Last week's Phase III miss in Parkinson's disease psychosis by pimavanserin, the 5-HT2A inverse agonist from Acadia Pharmaceuticals Inc. and Biovail Corp., shone the spotlight once again on the "better-than-expected placebo effect," a persistent biotech bugaboo - a hazard that makes investors and scientists cringe. Read More
